Monkeypox Virus Vaccine

Creative Biolabs is the industry's leading specialist in vaccine research with decades of experience in the development of poxvirus vaccines. The company has established a complete vaccine research and development system and leads a professional technical team. Under the guidance of rich experience, we can quickly and accurately solve all the problems encountered in the development of monkeypox vaccine for you.

Monkeypox Virus

The monkeypox virus is the causative agent of the infectious disease of monkeypox. The virus is a member of the Orthopoxvirus genus in the family Poxviridae. And its genome of is a double-stranded DNA. The disease caused by the virus is similar to but milder than smallpox and its mortality is often much lower. Humans and animals are both hosts for monkeypox virus and both species are vulnerable to the virus and may develop diseases. Monkeypox virus is mainly distributed in rainforests of west and central Africa. Isolates from Central Africa and Western Africa is different in virulence and the former is more virulent than the latter. The virus could spread in animals and humans and direct contact with the body fluid of an infected animal or being bitten may infect the virus.

Immune Responses for Protection against Monkeypox Virus Challenge

Previous studies show that smallpox vaccine-elicited antibodies are important and sufficient to protect immunized rhesus macaques against the challenge with monkeypox virus in a lethal dose. At the same time, after one month and six months of immunization, antibodies were used to block CD4⁺ and CD8⁺ T cells, so that they could not function normally, and the animals challenged with the lethal virus could survive. These results indicating that anti-vaccinia antibodies are enough to protect non-human primates from lethal challenge of monkeypox virus. Another study also supports the conclusion in which the Dayvax failed to protect the Dryvax-immunized macaques with immunodeficiency from monkeypox virus due to the short of B-cell response and failure of IgM-to-IgG switch in the case of detective CD4⁺ T helper cells. These findings suggest that when designing the monkeypox vaccine, we should focus on improving the humoral immune response of vaccine candidates and increasing antibody levels. Creative Biolabs has extensive experience in the development of poxvirus vaccines and has outstanding advantages in designing and improving the immunogenicity of vaccines. We provide all kinds of customized services to make your vaccine more effective.

The Development of the Monkeypox Vaccine

There are many studies involving monkeypox vaccines. A DNA vaccine named 4pox that comprised of L1R, A27L, A33r and B5R genes of VACA showed protection against lethal monkeypox virus challenge in rhesus macaques. Besides, an attenuated vaccinia virus LC16m8 which lacks membrane protein B5R is also protective. Subunit vaccines like DNA that encodes VACV L1R, A33, B5R, and A27L proteins could induce Th response and antibodies with a prime-boost immunization. And combination administration of these proteins is better protective against challenge by monkeypox virus than using them separately. In addition, the efficacy of the 4-valent vaccine is enhanced when formulated with the D8 protein of vaccinia virus. Recombinant proteins L1, B5 and A33 of vaccinia virus with adjuvant could induce neutralizing antibodies in immunized monkeys and cut down the morbidity compared to the control after challenge. Those proteins could also provide complete protection when adjuvanted with alum and CpG in nonhuman primates from lethal challenge with monkeypox virus. Nowadays, kinds of vaccines of monkeypox are being developed. They are DNA vaccines, multi-valent DNA cocktails, attenuated variola virus vaccine and recombinant vaccine Wyeth/IL-15 prepared by inserting human IL-15 cytokine gene into the genome of vaccinia virus (Wyeth strain), all of which are protective against lethal challenge by monkeypox virus. However, another vaccine that is made from New York City Board of Health vaccinia virus with deletion of the E3L gene, a gene related to innate immune evasion, could only present an incomplete protection in monkey model with a challenge by monkeypox virus.

Based on all the latest findings in the world and Creative Biolabs' own deep research and development experience and innovation, we now have the ability to design and prepare various types of monkeypox vaccines, enabling a wide range of in-depth immunological evaluation of the candidate vaccines. With a variety of strategies to improve the immunogenicity and protection of the vaccine, we can rationally design and optimize the formulation, dosage, route of administration and production process, etc. In addition to the practical application, we can also provide a series of toxicological and pathological analysis. These basic research services will help you better understand the virus and will assist you to make a safer and more effective monkeypox vaccine.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.